Nirosen Vijiaratnam

Head of Movement disorders service

Monash Health

Australia

Research Interests

Explore related searches

Professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nirosen Vijiaratnam is the Head of Movement Disorders Service at Monash Health, Australia. His research focuses on Parkinson's disease and related disorders, with recent publications addressing diagnostic and prognostic measures, the impact of depressive symptoms on treatment outcomes, and disease-modifying therapies, including the efficacy of exenatide. He is also involved in explorations of biomarker utilization in clinical trials and has contributed to studies on various treatment approaches for movement disorders.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (9)

Gordon Duncan

Consultant Physician / Hon Clinical Senior Lecturer / NRS Clinical Fellow

NHS England

UNITED KINGDOM

View details

Ludvic Zrinzo

Professor of Neurosurgery., Head Unit of Functional Neurosurgery

UCL Institute of Neurology, University College London

UNITED KINGDOM

View details

K Ray Chaudhuri

King’s College London

UNITED KINGDOM

View details

Camille Carroll

Clinical Professor

Newcastle University

UNITED KINGDOM

View details

David Crosiers

Professor at University of Antwerp

University of Antwerp

BELGIUM

View details

Joanne Trinh

Professor

University of Lübeck

GERMANY

View details

Thomas Foltynie

University College London

UNITED KINGDOM

View details

Marwan Hariz

University College London

UNITED KINGDOM

View details

Christopher Kobylecki

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nirosen Vijiaratnam

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Intronic FGF14 GAA repeat expansions impact progression and survival in multiple system atrophy.

Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study

Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease

Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early‐ to Mid‐Stage Parkinson's Disease Modification Trials

Frequency and outcomes of gastrostomy insertion in a longitudinal cohort study of atypical parkinsonism

Clinical outcomes after MRI connectivity-guided radiofrequency thalamotomy for tremor

How should we be using biomarkers in trials of disease modification in Parkinson’s disease?

Parkinson's disease tremor differentially responds to levodopa and subthalamic stimulation

Collaborators (9)

Gordon Duncan

Ludvic Zrinzo

K Ray Chaudhuri

Camille Carroll

David Crosiers

Joanne Trinh

Thomas Foltynie

Marwan Hariz

Christopher Kobylecki

Make your next move.